A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
The year 2019 brought new evidence supporting nonmedical switching from infliximab (Remicade) and etanercept (Enbrel) to biosimilars (CT-P13 and SB4, respectively) for inflammatory arthritis, plus research suggesting using positive messages with patients improves willingness to switch to biosimilars.
In a year-in-review article published in Nature Reviews Rheumatology, author Jonathan Kay of UMass Memorial Medical Center and the University of Massachusetts Medical School outlines studies published in last year on nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.1
Infliximab biosimilar CT-P13
In 2019, results were published from the 26-week open-label extension of the NOR-SWITCH trial,2 which had previously established similar efficacy and safety upon nonmedical switching from infliximab to biosimilar CT-P13 in 2017. In the extension of the trial, patients from the infliximab group were switched to CT-P13, and patients who had switched to CT-P13 remained on the biosimilar. Similar proportions of patients in the 2 groups experienced disease activity worsening. Rates of adverse events, infusion reactions, and antidrug antibodies were also similar, providing additional evidence supporting nonmedical switching from infliximab to its biosimilar CT-P13.
Real-world evidence for etanercept biosimilar SB4
In 2016, Denmark mandated etanercept be replaced with its lower-cost biosimilar SB4 in most patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. An observational cohort study published in 2019 revealed the real-world effects of this mandatory switch.3 There were no differences in disease activity comparing the 3 months before and after the switch, a smaller proportion of switched patients withdrew from treatment compared to those who remained on etanercept, and 1-year adjusted retention rates were similar. Reasons for switching back to etanercept were mainly subjective, and according to Kay, some switches back to the originator were likely due to the nocebo effect.
Communicating with patients about biosimilars
Also published in 2019 was a randomized controlled trial in New Zealand in which patients being treated with originator biologics received 1 of 4 video explanations on biosimilars, 2 with positive messaging and 2 negative. Those participants who saw a positively framed message were more than twice as willing to switch to a biosimilar and thought the biosimilar would be more effective compared to those who saw negative messages.4
Kay also notes the previously published BIO-SPAN study, in which staff were instructed to inform patients of cost savings and lower rate of injection site reactions associated with SB4; they were also trained to discuss the nocebo effect with patients. In that study, 99% of patients who were asked to switch to SB4 were willing to switch.5
According to the author, because the messages patients receive from healthcare providers shape their expectations, emphasizing the potential benefits of biosimilars may increase willingness to switch, reduce failure due to the nocebo effect, and improve medication persistence.
References:
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).